CPIX vs CODA

For growth investors, Coda Octopus Group, Inc.

(CODA) is the stronger pick with 30. 7% revenue growth year-over-year, versus 17. 6% for Cumberland Pharmaceuticals Inc. (CPIX). Coda Octopus Group, Inc. (CODA) offers the better valuation at 32. 2x trailing P/E (22. 5x forward), making it the more compelling value choice. Analysts rate Coda Octopus Group, Inc. (CODA) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cumberland Pharmaceuticals Inc.

(CPIX) delivered a total return of +62. 7%, compared to +49. 7% for Coda Octopus Group, Inc. (CODA). Over 10 years, the gap is even starker: CODA returned +844. 4% versus CPIX's -8. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Coda Octopus Group, Inc.

(CODA) is the lower-risk stock at 1. 00β versus Cumberland Pharmaceuticals Inc. 's 1. 09β — meaning CPIX is approximately 9% more volatile than CODA relative to the S&P 500. On balance sheet safety, Coda Octopus Group, Inc. (CODA) carries a lower debt/equity ratio of 1% versus 41% for Cumberland Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Coda Octopus Group, Inc.

(CODA) is pulling ahead at 30. 7% versus 17. 6% for Cumberland Pharmaceuticals Inc. (CPIX). On earnings-per-share growth, the picture is similar: Cumberland Pharmaceuticals Inc. grew EPS 58. 7% year-over-year, compared to 15. 6% for Coda Octopus Group, Inc.. Over a 3-year CAGR, CODA leads at 6. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Coda Octopus Group, Inc.

(CODA) is the more profitable company, earning 15. 5% net margin versus -6. 4% for Cumberland Pharmaceuticals Inc. — meaning it keeps 15. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CODA leads at 17. 1% versus -6. 3% for CPIX. At the gross margin level — before operating expenses — CPIX leads at 85. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Coda Octopus Group, Inc.

(CODA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 00), +844. 4% 10Y return). Both have compounded well over 10 years (CODA: +844. 4%, CPIX: -8. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CPIX (Healthcare) and CODA (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.